SEC Form 4 · accession 0001140361-18-000914

BIOMARIN PHARMACEUTICAL INC · BMRN

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President, Worldwide R&D

Period of report

Jan 2, 2018

Accepted (ET)

Jan 4, 2018 · 7:26 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001048477

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock^F1,F2	Jan 2, 2018	M	5,000	$26.49	A	138,976	D
Common Stock^F1	Jan 2, 2018	M	10,000	$37.46	A	148,976	D
Common Stock^F1,F3	Jan 2, 2018	S	15,000	$89.2267	D	133,976	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy Common Stock)^F1,F4	$26.49	Jan 2, 2018	M	5,000	D	Nov 12, 2011	May 11, 2021	Common Stock	5,000	5,225	D
Stock Option (right to buy Common Stock)^F1,F4	$37.46	Jan 2, 2018	M	10,000	D	Nov 8, 2012	May 7, 2022	Common Stock	10,000	27,331	D

F1Trade made pursuant to a 10b5-1 plan executed on May 9, 2017.
F2Amount of securities beneficially owned has been updated from the reporting person's prior report to: a) exclude 1,435 shares as previously reported in the Form 4 Amendment filed with the S.E.C. on 10/13/2017; and b) exclude 1,011 shares inadvertently included in prior reports based on a reconciliation with the Company's records.
F3The price in column 4 is the weighted average price. The price actually received ranged from $88.84 to $90.00. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
F4Reflects the number of options outstanding after the transactions from this specific stock option grant.